Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 11/20 | 0.51 |
| ▸ | CA1 | P00915 | 10/20 | 0.51 |
| ▸ | CA2 | P00918 | 10/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | ELF3 | P78545 | 1/20 | 0.45 |
| ▸ | MED23 | Q9ULK4 | 1/20 | 0.45 |
| ▸ | HTRA2 | O43464 | 2/20 | 0.44 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639566 | 0.98 | CA9 (0.49) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14306441 | 0.97 | CA9 (0.50) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13062142 | 0.95 | CA9 (0.49) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21335460 | 0.95 | CA9 (0.49) | CA9CA1CA2CA12CA14 | |
| SCHEMBL23716495 | 0.95 | CA9 (0.49) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14306442 | 0.93 | CA9 (0.53) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13946827 | 0.92 | FOLH1 (0.47) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13062140 | 0.91 | CA9 (0.52) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21982700 | 0.90 | ALB (0.47) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21183304 | 0.90 | FOLH1 (0.53) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2020-09-10 | — | — | US | disclosed |
| US-9951324-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2018-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283748-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA9 103/4885CA1 397/4885CA2 1844/4885 |
| US-11155800-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CA9 103/4885CA1 397/4885CA2 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.